- Home
- ICCM vs MAIA Comparison
ICCM vs MAIA Comparison
Compare ICCM & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCM
- MAIA
- Stock Information
- Founded
- ICCM 2006
- MAIA 2018
- Country
- ICCM Israel
- MAIA United States
- Employees
- ICCM N/A
- MAIA N/A
- Industry
- ICCM
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- ICCM
- MAIA Health Care
- Exchange
- ICCM Nasdaq
- MAIA Nasdaq
- Market Cap
- ICCM 61.1M
- MAIA 56.3M
- IPO Year
- ICCM N/A
- MAIA 2022
- Fundamental
- Price
- ICCM $0.83
- MAIA $1.52
- Analyst Decision
- ICCM Strong Buy
- MAIA
- Analyst Count
- ICCM 1
- MAIA 0
- Target Price
- ICCM $2.50
- MAIA N/A
- AVG Volume (30 Days)
- ICCM 2.6M
- MAIA 436.2K
- Earning Date
- ICCM 08-13-2025
- MAIA 08-19-2025
- Dividend Yield
- ICCM N/A
- MAIA N/A
- EPS Growth
- ICCM N/A
- MAIA N/A
- EPS
- ICCM N/A
- MAIA N/A
- Revenue
- ICCM $3,273,000.00
- MAIA N/A
- Revenue This Year
- ICCM $75.27
- MAIA N/A
- Revenue Next Year
- ICCM $129.39
- MAIA N/A
- P/E Ratio
- ICCM N/A
- MAIA N/A
- Revenue Growth
- ICCM 0.34
- MAIA N/A
- 52 Week Low
- ICCM $0.48
- MAIA $1.40
- 52 Week High
- ICCM $1.66
- MAIA $3.74
- Technical
- Relative Strength Index (RSI)
- ICCM 29.89
- MAIA 38.13
- Support Level
- ICCM $0.87
- MAIA $1.46
- Resistance Level
- ICCM $1.07
- MAIA $1.60
- Average True Range (ATR)
- ICCM 0.07
- MAIA 0.07
- MACD
- ICCM -0.02
- MAIA -0.02
- Stochastic Oscillator
- ICCM 0.26
- MAIA 14.12
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.